• Nem Talált Eredményt

Bio-Activation

In document Section LB (Pldal 25-30)

I n t h e foregoing, t h e detoxication aspects of drug metabolism were discussed.

Now, attention will be paid to bio-activation. Bio-activation means a change in t h e chemical properties of t h e drug, so t h a t new pharmacological actions are introduced into its spectrum of activity. This m a y be accompanied by t h e loss of its original bio-tropic properties.

One of t h e bio-activations first recognized as such was t h a t of Prontosil R u b r u m (4'-sulfamyl-2,4-diaminoazobenzene hydrochloride), t h e compound found by Domagk (56a) t o be effective in t h e protection of mice against bacterial infections. The drug was inactive when tested in vitro. The cause of t h e dif­

ference in activity appeared t o be t h e change of t h e drug by t h e mice from an inactive to an active form—a bio-activation (Fig. 7). Prontosil is metabolized t o sulfanilamide as a consequence of t h e reduction of t h e azo configuration in prontosil (196a). A large number of highly effective sulfanilamide derivatives have been developed since then. Sulfanilamide and most of its derivatives are acetylated in t h e body and then become ineffective as far as t h e infection—

therefore, their action upon t h e microorganisms—is concerned. This time, t h e bio-inactivation performed by t h e host is of advantage to t h e parasite.

From t h e various arsenicals used against spirochetal and protozoal infec­

tions, t h e arsenoso compounds ( R — A s = 0 ) have a direct parasiticidal effect.

The other arsenicals are only effective after conversion to arsenoso compounds.

Depending on t h e drug used t h e bio-activation is based on a reduction in t h e

78 Ε . J . A RI E NS AND Α. Μ. SIMONIS N H2

Ο c - c — Ο S / / \ \ _ M = M - / / V LN H. «« «*ro inactive V * H„N—('fi x 7 N> - N = Ν — ( x 7 x 2>-s — N H in vivo activated / \ / / v\ 2 " 1 ν w ; : ' PV

Ο ι C - C - Ο Ο - / / \ \ - N O , prontosil rubrum | parathion

reduction bio-activation oxidation

/ / ~ \ - K U

I

v _ / ^ ~ ~ ^ V - ! L v u iw w/ro active \ ^

ι ι

f c - c - o 1

-NH2 H2N —( V S - N H - .*x 7 " * in vivo active y \ 1 . ~ ~ "VC PV

sulfanilamide

c—c—o o-^v y—NO,

paraoxon

acetylation bio-inactivation hydrolysis

1 I I

|r . . Ο J C - C — Ο T O

c_clN_ y / VS_NH2 inactive ^ / / Κ 2 ?:« ?u?>o inactive , \ / / \ \

Ο Λ ' Ο C—C—Ο OH HO—Γ X\ - N 02

JV4 acetyl sulfanilamide

FIG. 7. Bio-activation and bio-inactivation.

case of t h e p e n t a v a l e n t acids ( R — A s 03H2) or on a n o x i d a t i o n in case of t h e arseno c o m p o u n d s ( R — A s = A s — R ' ) (62).

T h e r e l a t i o n s between s t r u c t u r e a n d t o x i c i t y in v a r i o u s series of a l i p h a t i c fluorine c o m p o u n d s a r e i n s t r u c t i v e (see T a b l e X ) . T h e d e r i v a t i v e s w i t h a n odd n u m b e r of m e t h y l e n e groups in t h e chain can be d e g r a d e d b y β - o x i d a t i o n

T A B L E X

ALTERNATION IN TOXICITY OF ALIPHATIC-CU-FLUORINE COMPOUNDS0

F(CH2)nCOOH F(CH2)nCHO F(CH2)nCH2OH F(CH2)MCH3

η Odd* Even6 Odd Even Odd Even Odd Even

1 6.6 6 10

2 60 46.5 3 0.65 2 0.9

4 > 100 81 > 100

5 1.35 0.58 1.2 1.7 6 40 > 100 80 35 7 0.64 2 0.6 2.7

8 > 100 53 32 21.7 9 1.5 1.9 1 1.7 10 57 > 4 0 > 1 0 0 15.5 11 1.25 1.5 2.5

A L D60 for mice in mg/kg intraperitoneally. From Pattison (146a).

b Toxicity in mg/kg for odd and even values of n.

Ι , Ι . Β . DRUG T R A N S F E R E N C E : DRUG METABOLISM 79 under formation of t h e highly toxic fluoroacetic acid (see Section I.B.5.2.) The compounds with a n even n u m b e r of methylene groups lead t o t h e relatively nontoxic j8-fluoropropionic acid. The consequences of these bio-transforma­

tions are reflected in t h e toxicities summarized in Table X .

An i m p o r t a n t example of a bio-activation b y reduction is found among t h e adrenal cortical steroid hormones a n d t h e synthetic drugs of t h a t group. The antirheumatic steroids, cortisone a n d prednisone, are practically inactive if applied locally, in t h e joints. The corresponding " h y d r o " compounds, hydro­

cortisone a n d prednisolone, are highly active if applied by this route. Ad­

ministered orally, cortisone a n d prednisone are as effective as t h e hydro compounds, since t h e y are metabolized in t h e liver t o hydrocortisone a n d prednisolone, respectively (see Fig. 8). Consequently, t h e oral route, which ascertains rapid reduction through early action b y t h e liver, is even more effective t h a n will be subcutaneous injection. I n this case, too, bio-activation is followed by an inactivation, partially because of conjugation with glucuronic acid (149).

Progesterone is metabolized mainly t o pregnanediol. This is a highly active pyrogenic steroid (111a). Possibly, t h e rise in body t e m p e r a t u r e during t h e progestational phase of t h e menstrual cycle is due t o this metabolite. Various aspects of steroid metabolism in relation t o steroid structure a n d t h e conse­

quences of these bio-transformations are discussed in a thoughtful review b y Berliner (20b).

Some physiologically i m p o r t a n t bio-activations are t h e decarboxylation of dihydroxyphenylalanine (DOPA) t o dopamine, a precursor of norepinephrine a n d epinephrine, of histidine t o histamine, a n d of 5-hydroxytryptophan t o 5-hydroxytryptamine (serotonin). These amino acids can cross t h e blood-brain barrier; t h e amines formed from t h e m cannot.

Deamination practically always results in an inactivation, however, dealkyl-ation of amines often results in active compounds. Most sympathomimetics are active as free amines as well as methylamines. Compare, for instance, norepine­

phrine a n d epinephrine, norephedrine a n d ephedrine, a m p h e t a m i n e a n d meth-a m p h e t meth-a m i n e . Demethylmeth-ation of t h e meth-amino group in morphine meth-and other narcotics results in a decrease of activity (15,121,133). Dealkylation of ring-bound alkoxy groups, which results in an unmasking of phenolic OH-groups, often leads t o active compounds. Deethylation of phenacetine gives iY-acetyl-p-aminophenol, demethylation of codeine gives morphine, etc. Dealkylations are oxidative processes.

Other examples of bio-activation are t h e introduction of phenolic OH-groups a n d t h e oxidation of phosphorothionates among t h e insecticides. P a r a t h i o n , an acetylcholinesterase-inhibitor, inactive in vitro b u t active in vivo, is oxidized by t h e liver t o paraoxon, which is active in vitro as well as in vivo—a bio-activa­

tion. Paraoxon, in its t u r n , is metabolized rapidly by t h e liver a n d inactivated (143) (Fig. 7). The toxicity of both compounds, therefore, varies with t h e route

80 Ε. J . ARIENS AND A. M. SIMONIS

of administration. A comparison of t h e intramuscular and intraperitoneal route demonstrates t h a t parathion is least toxic given intramuscularly; para-oxon is least toxic given intraperitoneally (93).

A rather complicated t y p e of bio-activation by oxidation is found in the

ug/100ml Plasma —— — A Hydrocortisone after 200 mg hydrocortisone orally

ο c J r U s o n ^0^ }0^ 2 09 cortisone orally 0 m

200

150

100 Η

50

60 120 180 240 minutes

FIG. 8. Concentration of cortisone and hydrocortisone in plasma after oral administra­

tion. Note the high concentration of hydrocortisone after administration of cortisone (149).

toxic syndrome caused by ethyl alcohol after Antabus (tetraethylthiuramdi-sulfide), also called Refusal. The toxic symptoms are caused by acetaldehyde, formed from t h e alcohol by oxidation. Acetaldehyde is a normal intermediate in metabolism of alcohol. Normally, however, t h e concentration remains far below t h e toxic level, because of t h e rapid conversion into acetic acid by an aldehyde dehydrogenase in t h e liver. Only after this enzyme is inhibited by Refusal, can a toxic concentration of acetaldehyde be reached in t h e body. The

Ι , Ι . Β . DRUG T R A N S F E R E N C E : DRUG METABOLISM 81 discomfort caused by alcohol after Refusal, makes t h e drug suitable for forcing alcoholics to refuse alcohol (that is, if t h e y do not refuse their Refusal) (97, 146b).

A bio-activation as a result of hydrolysis m a y be expected after administra­

tion of esters of various steroid hormones, used as storage-depot preparations (55, 136). The ester group often blocks OH-groups essential to activity. This makes hydrolysis necessary. The variations in activity of the several esters

β - naphthy lamine non- carcinogenic

a h y d r o x y -β - naphthy lamine

carcinogenic

conjugation with glucuronic acid

(liver)

C6H1 0O6

Ο

NH2 h y d r o l y s i s by β -glucuronidase

(urine)

OH

glucuronide non-carcinogenic

α-hydroxy-β - naphthy lamine

carcinogenic FIG. 8. A. Bio-activation, inactivation, and reactivation as sequential steps in metabol­

ism of jS-naphthylamine. Boyland (25a).

must be a t t r i b u t e d to t h e variation in the rate of absorption a n d in distribution in t h e tissues, as well as to a variation in t h e r a t e of hydrolysis of t h e esterified steroid (217). Another example of bio-activation by hydrolysis is: acetyl-salicylic acid, readily hydrolyzed by plasma enzymes, liberates free acetyl-salicylic acid. A great variety of esters are susceptible to plasma esterases (123).

While t h e excretion of drugs in urine usually results in an absolute removal, excretion in t h e bile often means t h a t t h e drug is reabsorbed from t h e intestines and enters circulation again. This is known as t h e hepato-enteric circuit. I t sometimes happens t h a t a conjugated drug excreted in t h e bile is split in t h e intestines converting it into its free form. The free drug is t h e n reabsorbed.

This is a special t y p e of bio-activation. I t happens, for instance, with t h e con­

jugation products of phenolic estrogens (165).

β-Naphthylamine and various other aromatic amines can cause cancer of t h e

82 Ε. J. ARIENS AND A. M. SIMONIS

bladder, an occupational disease of workers in dye factories (79a). The meta­

bolic conversion of these amines to o-hydroxy derivatives seems t o play a role in this carcinogenic action (207a). Metabolic processes possibly also play a p a r t in t h e localization of t h e cancer in t h e bladder (25a). A bio-activation of an originally inactive conjugation product takes place in t h e bladder (Fig. 8A).

The glucuronide mentioned is not the only potential carcinogenic product formed; t h e sulfate of α-hydroxy-j8-naphthylamine can also serve as a pre­

cursor. This conjugation product, however, is n o t hydrolyzed b y urinary arylsulfatase. Urine of patients with cancer of t h e bladder contains a relatively high concentration of ^-glucuronidase. This suggests t h a t an action of this enzyme is a cofactor in carcinogenesis in these cases. Glucosaccharo-1,4-lactone, a potent competitive inhibitor of t h e enzyme has been tried for prophylactic t r e a t m e n t (25a, 128a, 171b). Some investigators deny the role of ^-glucuronidase in bladder carcinogenesis (183c).

Conjugation very seldom brings a b o u t bio-activation. The decreased water-solubility of sulfanilamides after acetylation, with an increased risk of crystal-luria is often mentioned as an example of increased toxicity by conjugation.

B y masking t h e anilide group, t h e process becomes one of bio-inactivation.

The damage from crystalluria, a purely mechanical effect, cannot be counted as a pharmacological effect in t h e strict sense.

In document Section LB (Pldal 25-30)